The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s ...

The company employs machine learning to uncover disease mechanisms at the mRNA level and to identify therapeutic candidates.

Emergent said it is separately working on increasing the availability of its overdose reverser on site for businesses.

As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK.

The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism ...

City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based ...

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) ...

The manufacturing shift to meet growing cell and gene therapy demand, applying lessons from the Covid-19 pandemic to address ...

Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to clinic.

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

Bayer has entered a collaboration with MOMA Therapeutics in which the two companies will advance a small molecule oncology ...